|
|
Gene Therapy: Current Status and ProspectsPublished by: Drug and Market Development Publishing Published: Jun. 1, 2005 - 198 Pages Table of ContentsChapter 1: Executive Summary Adverse Events in Gene Therapy The Case of Jesse at University of Pennsylvania x-Severe Combined Immunodeficiency Syndrome (x-SCID) Approval of First Gene Therapy Product: Gendicine Adenovirus Takes p53 Gene into Malignant Cells Additional Good News Latest Development Managing Regulatory Issues in Europe Why Gene Therapy has not been Successful Recent Developments in Gene Therapy Research Chapter 2: Market Prospects for Gene Therapy Chapter 3: Introduction and Background to Gene Therapy The Science Behind Gene Therapy Delivery Mechanism in Gene Therapy In Vivo Ex Vivo Viral Delivery Systems Adenoviruses Adeno-Associated Viruses Herpes Simplex Virus Lentivirus Vectors HIV-Based Vectors Lentiviral Packaging Systems Lentiviral Vectors for Hematopoietic Stem Cells Diseases Treated by Viral Methods of DNA-transfer Gene Therapy for Cystic Fibrosis Liver-Directed Gene Therapy Therapy Against Retinitis Pigmentosa Non-Viral Methods of DNA Transfer Promoter Control for Gene Therapy Chapter 4: Gene Therapy for Human Diseases Gene Therapy for Cancer Immuno-potentiation Oncogene Inactivation Tumor Suppressor Gene Molecular Chemotherapy Drug Resistance Gene Therapy of Cystic Fibrosis Wild-type Dominant Allele F of the CFTR Gene Gene Therapy for Transplantation Gene Therapy for HIV The Challenges in HIV Gene Therapy for HIV: Work in Progress University of Pennsylvania Study Clinical Trial Status of Gene Therapy Chapter 5: Expert Opinions Alain P. Rolland, Pharm D., Ph.D., Vical Incorporated Dr. Brian Salmons, Ph.D., Science and Technology Dr. Jan J. Boesen, Ph.D.,Amsterdam Molecular Therapeutics BV Douglas Jolly Ph.D., Advantagene Inc. Dr. Nay Wei Soong, Ph.D., Maxygen Inc. Xiaobin Lu, Ph.D., VIRxSYS Corporation Ruxandra Draghia, MD, Ph.D., Advisys, Inc. Chapter 6: Company Profiles Advantagene AdViSYS Inc. Aldevron Inc. AMDL Inc. Amsterdam Molecular Therapeutics BV Angiogene Inc, Ark Therapeutics plc Athersys Inc Austrianova BioMedica Inc. Cell Genesys, Inc. Ceregene Inc. Corautus Genetics Epeius Biotechnologies Inc. GenVec, Inc. Introgen Therapeutics Targeted Genetics Corporation Vical Incorporated VIRxSYS Corporation Appendix 1: Companies Operating in the GT Space 1 Appendix 2: Gene Therapy Experts Appendix 3: Patents in Gene Therapy Appendix 4: Recent Headlines in Gene Therapy Genetically Engineered Mouthwash May Delay Oral Cancer Gene Therapy Appears Effective for Recurrent Head and Neck Cancer Correction of Rapid Growth of Cancer Cells: One Approach Involves The Use of “Antisense Oligonucleotides” ‘Bubble Boy’ Saved By Gene Therapy Appendix 5: Literature and Additional Reading AbstractThis Report provides a detailed breakdown of the applications and markets for gene therapy as well as an analysis of future growth trends. The Report details the latest developments of pre-clinical and clinical status in gene therapy areas. Delivery mechanisms in gene therapy such as viral and non-viral delivery systems are described in detail. The FDA regulation of gene therapy is overviewed as well. The Report contains company profiles as well as expert opinions from those active in this area.Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||